Free Trial

Agios Pharmaceuticals (AGIO) Competitors

Agios Pharmaceuticals logo
$35.35 +0.98 (+2.85%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$35.35 +0.00 (+0.00%)
As of 07/2/2025 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AGIO vs. BBIO, ROIV, RVMD, ELAN, LEGN, GRFS, TLX, TGTX, LNTH, and NUVL

Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), TG Therapeutics (TGTX), Lantheus (LNTH), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

Agios Pharmaceuticals vs. Its Competitors

Agios Pharmaceuticals (NASDAQ:AGIO) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Agios Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agios Pharmaceuticals$36.50M56.10$673.72M$11.243.15
BridgeBio Pharma$221.90M36.65-$535.76M-$3.53-12.13

Agios Pharmaceuticals has a net margin of 1,798.26% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals1,798.26% -2.75% -2.52%
BridgeBio Pharma -524.25%N/A -94.43%

99.9% of BridgeBio Pharma shares are owned by institutional investors. 4.3% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Agios Pharmaceuticals currently has a consensus price target of $58.60, suggesting a potential upside of 65.77%. BridgeBio Pharma has a consensus price target of $58.85, suggesting a potential upside of 37.39%. Given Agios Pharmaceuticals' higher possible upside, equities research analysts clearly believe Agios Pharmaceuticals is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
BridgeBio Pharma
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93

Agios Pharmaceuticals has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.

In the previous week, BridgeBio Pharma had 4 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 21 mentions for BridgeBio Pharma and 17 mentions for Agios Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.56 beat Agios Pharmaceuticals' score of 0.23 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agios Pharmaceuticals
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BridgeBio Pharma
8 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

BridgeBio Pharma beats Agios Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Agios Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGIO vs. The Competition

MetricAgios PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.99B$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio3.1521.3126.1719.90
Price / Sales56.10278.47413.55113.66
Price / CashN/A41.4736.1356.90
Price / Book1.317.518.025.38
Net Income$673.72M-$55.05M$3.15B$248.50M
7 Day Performance5.05%2.07%1.48%2.06%
1 Month Performance5.93%4.84%3.66%4.86%
1 Year Performance-15.87%5.37%34.68%20.24%

Agios Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGIO
Agios Pharmaceuticals
4.067 of 5 stars
$35.35
+2.9%
$58.60
+65.8%
-15.9%$1.99B$36.50M3.15390
BBIO
BridgeBio Pharma
4.7128 of 5 stars
$42.17
+1.1%
$56.67
+34.4%
+71.9%$7.92B$221.90M-11.95400Analyst Forecast
Insider Trade
ROIV
Roivant Sciences
1.9443 of 5 stars
$11.50
+0.4%
$17.50
+52.2%
+3.9%$7.78B$29.05M-46.00860
RVMD
Revolution Medicines
4.4993 of 5 stars
$40.04
+1.0%
$67.08
+67.5%
-0.5%$7.39B$11.58M-10.01250Analyst Revision
ELAN
Elanco Animal Health
2.3429 of 5 stars
$13.36
-0.7%
$15.17
+13.5%
+5.1%$6.68B$4.44B18.059,000Analyst Forecast
LEGN
Legend Biotech
3.4951 of 5 stars
$33.85
-0.4%
$76.20
+125.1%
-19.7%$6.25B$627.24M-57.372,609News Coverage
Positive News
Analyst Forecast
GRFS
Grifols
4.137 of 5 stars
$8.37
-4.6%
$10.30
+23.1%
+40.2%$6.03B$7.81B7.1523,822
TLX
Telix Pharmaceuticals
N/A$16.39
-4.4%
$22.00
+34.2%
N/A$5.80B$516.72M0.00N/AGap Down
High Trading Volume
TGTX
TG Therapeutics
3.7706 of 5 stars
$36.56
+1.5%
$40.80
+11.6%
+98.2%$5.72B$329M152.33290
LNTH
Lantheus
4.4515 of 5 stars
$80.81
+2.0%
$130.50
+61.5%
+1.4%$5.48B$1.53B22.96700Positive News
NUVL
Nuvalent
3.736 of 5 stars
$75.98
+1.3%
$115.50
+52.0%
+10.3%$5.39BN/A-17.3140Analyst Upgrade
Insider Trade

Related Companies and Tools


This page (NASDAQ:AGIO) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners